Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2003
12/24/2003CA2488117A1 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003CA2487948A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators
12/24/2003CA2464109A1 Process for the preparation of oxazolidinones and method of use thereof
12/23/2003US6667404 Retroviral protease inhibiting compounds
12/23/2003US6667393 Azalide antibiotic compositions
12/23/2003US6667341 Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters; anticancer agents, hemological disorders, and inherited metabolic disorders
12/23/2003US6667335 NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers
12/23/2003US6667325 P38MAP kinase inhibiters; tumor necrosis factor alpha, interleukin 1 and 6 and cyclooxygenase II related diseases
12/23/2003US6667320 For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV)
12/23/2003US6667316 Pharmaceutically active isoindoline derivatives
12/23/2003US6667314 Tropane derivatives useful in therapy
12/23/2003US6667312 Thioether substituted imidazoquinolines
12/23/2003US6667300 Purinyl substituted quinazoline-4-one derivatives
12/23/2003US6667295 DNA vaccine against feline immunodeficiency virus
12/23/2003US6667151 Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease
12/23/2003US6667053 D and L etherlipid stereoisomers and liposomes
12/23/2003US6667035 Isolated polypeptide which specifically binds and neutralizes Clostridium difficile enterotoxin (toxin A)
12/23/2003US6667033 Administering daily effective dose of interferon-beta in two portions for four weeks
12/23/2003CA2087084C Esters of acyl carnitines with long-chain aliphatic alcohols and pharmaceutical compositions containing same having antimycotic activity
12/23/2003CA2059063C Novel antiviral compounds
12/18/2003WO2003104807A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003WO2003104467A1 Means and methods for the production of adenovirus vectors
12/18/2003WO2003104440A2 2,2-bis(hydroxymethyl)cyclopropylidenemethyl - purines and -pyrimidines as antiviral agents
12/18/2003WO2003104262A2 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells
12/18/2003WO2003104260A2 Pharmaceutical formulation
12/18/2003WO2003104230A1 Bicyclic pyrimidine derivatives
12/18/2003WO2003104229A1 Novel fused imidazole derivative
12/18/2003WO2003104223A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003WO2003104222A1 Bisindolyl-maleimid derivatives as kinase inhibitors
12/18/2003WO2003104221A1 Inhibitors of the gpib -vwf interaction, their preparation and use
12/18/2003WO2003104219A1 Nf-kb inhibitors
12/18/2003WO2003104218A1 Nf-:b inhibitors
12/18/2003WO2003104209A1 Peptide deformylase inhibitors
12/18/2003WO2003104205A1 Aryloximes
12/18/2003WO2003104204A1 Pyridazine derivatives
12/18/2003WO2003104178A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
12/18/2003WO2003103822A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003WO2003103708A1 BIOFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION
12/18/2003WO2003103691A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003WO2003103687A1 Liquid formulation of decitabine and use of the same
12/18/2003WO2003103671A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/18/2003WO2003103668A1 Pyridin-2-one and quinolin-2-one derivatives, preparation thereof and use thereof as antibacterials
12/18/2003WO2003103636A1 A novel drug dosing regimen
12/18/2003WO2003103608A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003WO2003103590A2 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003WO2003103588A2 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003WO2003103584A2 Ether substituted imidazopyridines
12/18/2003WO2003103583A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003WO2003103577A2 Novel recombinant anticoagulant proteins
12/18/2003WO2003103571A2 Flavivirus vaccines
12/18/2003WO2003103398A1 Insecticidal amides with nitrogen-containing benzo-fused bicyclic ring systems
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003089446A3 23-o-substituted 5-o-mycaminosyltylonide derivatives
12/18/2003WO2003087087A3 Heterocyclic compounds and their use as modulators of p38 map kinase
12/18/2003WO2003077881A3 Method for production of phytoalexins
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003074467A3 Urea derivatives as hiv aspartyl protease inhibitors
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003066593A3 Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
12/18/2003WO2003064431A3 Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
12/18/2003WO2003061704A3 Combination therapy for the treatment of bacterial infections
12/18/2003WO2003059953A3 Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
12/18/2003WO2003058248A3 Diagnostics and vaccines for mycrobacterium paratuberculosis infections
12/18/2003WO2003057135A3 Aqueous compositions containing metronidazole
12/18/2003WO2003051306A3 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
12/18/2003WO2003045363A3 Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
12/18/2003WO2003045362A3 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
12/18/2003WO2003044047A3 Virulence proteins of the genus yersinia and uses thereof
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003040726A3 Screening for hepatitis c virus entry inhibitors
12/18/2003WO2003039444B1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
12/18/2003WO2003037164A3 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003026693A3 Inhibitors of costimulation by 0x40 and their use against infectious diseases
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002101049A3 Interleukin-18 mutants, their production and use
12/18/2003WO2002078599A3 CD8α + LYMPHOID DENDRITIC CELL DIFFERENTIATED FROM HUMAN HEMATOPOIETIC STEM CELL AND A METHOD FOR DIFFERENTIATION
12/18/2003WO2002058723A3 Chemokines as adjuvants of immune response
12/18/2003WO2002054072A3 Assay to determine efficacy of treatment for mycobacterial infection
12/18/2003WO2002042443A3 Use of modulators of eukaryotic signal transduction pathways for the treatment of helicobacter infections
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002014536A9 Odulating multiple lineage kinase proteins
12/18/2003WO2001078648A3 6-methylnicotinamide derivatives as antiviral agents
12/18/2003US20030232986 Inhibitors of caspases
12/18/2003US20030232893 Method of treating rosacea
12/18/2003US20030232887 Preparation and use of a stable formulation of allosteric effector compounds
12/18/2003US20030232865 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232851 Viral treatment
12/18/2003US20030232850 Heterocyclic amines such as 2-benzoyl-1,3,4,9-tetrahydro-2H-pyrido(3,4-b)indole, used preferential inhibitors of fatty acid biosynthesis in bacterial systems; bactericides
12/18/2003US20030232849 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232842 Nitrogen compounds such as methyl 4-(2-chloro-4-fluorophenyl) -2-(3,5-difluoropyridin-2-yl)-6-(4-morpholinylmethyl)-1,4-dihydropyrimidine -5-carboxylate, with mixtures of lamivudine and interferons, used as viricides; hepatitis
12/18/2003US20030232840 Oxazolidinone photoaffinity probes
12/18/2003US20030232830 Non-covalent inhibitors of AmpC beta-lactamase
12/18/2003US20030232816 Benzimidazole derivatives
12/18/2003US20030232815 Non-peptidic cyclophilin binding compounds and their use
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232812 Microbiocides used to treat eye and skin infections
12/18/2003US20030232803 Crystalline 1-methylcarbapenem derivatives
1 ... 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 ... 1798